Consistently, we uncovered that TROP2 was highly expressed (94.6%) in a ESCC cohort of 222 patients with a majority of cases (56.3%) presenting with moderate to high TROP2 expression. Here, TACSTD2 is linked to esophageal squamous cell carcinoma.